S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech and life sciences companies.
* CSPC Pharmaceutical Group Ltd. said Pan Weidong will cease to be rotating CEO and will continue to serve as the company's vice chairman and executive director. CSPC appointed its executive director Wang Zhenguo to serve as vice chairman and rotating CEO.
* Medicamen Biotech Ltd. said Himanshu Bansal resigned from his position as CFO, effective May 28. The New Delhi-based drugmaker said it will name Bansal's successor within due time.
* Prothena Corp. PLC said Tara Nickerson will leave the company as chief business officer July 1. Nickerson's departure is a part of the company's reorganization and workforce reduction plan, which will reduce its workforce by 75 employees.
* Revance Therapeutics Inc. said Lauren Silvernail resigned as the company's chief business officer and CFO. The company said certain members of management and its existing finance team will assume the duties and responsibilities of the office on an interim basis.
* Jane Henderson will leave Voyager Therapeutics Inc. as CFO and senior vice president of corporate development June 8. The company said its vice president of finance, Allison Dorval, will assume the roles of principal financial officer and principal accounting officer.
* Rigel Pharmaceuticals Inc. appointed Dean Schorno executive vice president and CFO.
* Avant Diagnostics Inc. appointed Jeffrey Busch chairman of the board and Mick Ruxin as president, CEO and a director.
* AzurRx BioPharma Inc. appointed James Pennington to the position of chief medical officer.
* TRACON Pharmaceuticals Inc. named Mark Wiggins its chief business officer.
* Elanix Biotechnologies AG appointed Egon Minar CFO and COO.
* Evolus Inc. appointed Lauren Silvernail CFO and executive vice president of corporate development.
* Ritter Pharmaceuticals Inc. named John Beck its CFO.
* ImmunoPrecise Antibodies Ltd. appointed Charles Wheelock its global chief technology officer.
* Protagonist Therapeutics Inc. appointed Samuel Saks its chief development officer.